FDA Peptide Update: Category 2 Removals Explained Peptides, explained: Answers to your top questions The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is FDA to weigh easing limits on unproven peptides promoted by RFK Jr. FDA considers adding a dozen peptides to its bulk drug compounding list RAPS